Edgewise Therapeutics (EWTX) Depreciation & Amortization (CF) (2020 - 2026)

Edgewise Therapeutics has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $537000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $537000.0, up 4.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (down 1.66% YoY), and the FY2025 annual result was $2.1 million, changed 0.0% from the prior year.
• Depreciation & Amortization (CF) came in at $537000.0 for Q1 2026 at Edgewise Therapeutics, down from $541000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $600000.0 in Q4 2024 to a low of $100000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $500000.0 (2024), against an average of $387882.4.
• Across the five-year window, Depreciation & Amortization (CF) surged 302.5% in 2023 and retreated 9.83% in 2025, its largest moves.
• Edgewise Therapeutics' Depreciation & Amortization (CF) stood at $120000.0 in 2022, then soared by 302.5% to $483000.0 in 2023, then rose by 24.22% to $600000.0 in 2024, then fell by 9.83% to $541000.0 in 2025, then dropped by 0.74% to $537000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $537000.0 (Q1 2026), $541000.0 (Q4 2025), and $500000.0 (Q3 2025), per Business Quant data.